Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02810951 · ClinicalTrials.gov registry record · Phase 1
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 1 study, sponsored by Castle Creek Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02810951 is a Phase 1 study that was terminated before completion, run by Castle Creek Biosciences. The registered enrollment target is 6 participants.
The verdict
NCT02810951, a Phase 1 study, was terminated before completion, sponsored by Castle Creek Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FDA OOPD
Interventions
- GENETIC FCX-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02810951
The ClinicalTrials.gov registry entry for NCT02810951 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FCX-007 is the first listed.
NCT02810951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02810951 about?
NCT02810951 is a clinical study titled "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)". The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FD...
What is the current status of trial NCT02810951?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-07-01. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT02810951?
The interventions under investigation include: FCX-007 (GENETIC).
Who is sponsoring clinical trial NCT02810951?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.